Key result
Levosimendan improves hemodynamics and symptoms in decompensated heart failure by increasing calcium sensitivity, though its long-term impact on mortality requires further large-scale studies.
Why the study?
Does levosimendan improve hemodynamics and symptoms in patients with decompensated heart failure?
Population
Patients with decompensated heart failure
Design
Review
Authors
Loading...
May support short-term levosimendan use in decompensated HF; leaves mortality effects open for larger trials.
Does levosimendan improve hemodynamics and symptoms in patients with decompensated heart failure?
Levosimendan is a promising calcium sensitizer that improves hemodynamics and symptoms in decompensated heart failure, though its long-term mortality impact requires further study.
Kota et al. (2008) conducted a review in Decompensated heart failure. Levosimendan was evaluated. Levosimendan improves hemodynamics and symptoms in decompensated heart failure by increasing calcium sensitivity, though its long-term impact on mortality requires further large-scale studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: